1. Home
  2. DCOY vs LABT Comparison

DCOY vs LABT Comparison

Compare DCOY & LABT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Decoy Therapeutics Inc. Common Stock

DCOY

Decoy Therapeutics Inc. Common Stock

N/A

Current Price

$1.10

Market Cap

674.8K

Sector

Health Care

ML Signal

N/A

Logo Lakewood-Amedex Biotherapeutics Inc. Common Stock

LABT

Lakewood-Amedex Biotherapeutics Inc. Common Stock

N/A

Current Price

$0.20

Market Cap

670.6K

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
DCOY
LABT
Founded
N/A
2006
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
674.8K
670.6K
IPO Year
2014
2026

Fundamental Metrics

Financial Performance
Metric
DCOY
LABT
Price
$1.10
$0.20
Analyst Decision
Analyst Count
0
0
Target Price
N/A
★ $7.50
AVG Volume (30 Days)
74.1K
★ 607.7K
Earning Date
11-16-2026
11-18-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ N/A
EPS
N/A
★ N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$20.42
N/A
P/E Ratio
★ N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.53
$0.22
52 Week High
$67.68
$6.85

Technical Indicators

Market Signals
Indicator
DCOY
LABT
Relative Strength Index (RSI) 33.76 16.87
Support Level $0.53 N/A
Resistance Level $3.29 $2.13
Average True Range (ATR) 0.11 0.06
MACD 0.06 0.01
Stochastic Oscillator 32.71 1.52

Price Performance

Historical Comparison
DCOY
LABT

About DCOY Decoy Therapeutics Inc. Common Stock

Decoy Therapeutics Inc is a pre-clinical stage biotechnology company focused on advancing its pipeline of peptide conjugate therapeutics engineered through its proprietary IMP3ACT platform. The IMP3ACT platform represents a paradigm shift in peptide conjugate drug discovery and manufacturing, leveraging machine learning (ML) and artificial intelligence (AI" tools alongside high-speed synthesis techniques to rapidly engineer, optimize and manufacture peptide conjugates that target serious unmet medical needs. The company manages its business in one operating segment, focused on the discovery and development therapeutics for patients with high, unmet medical needs. Its pipeline programs include: Pan-Coronavirus; and Tripledemic.

About LABT Lakewood-Amedex Biotherapeutics Inc. Common Stock

Lakewood-Amedex Biotherapeutics Inc is a clinical-stage biotechnology company developing a novel class of fast-acting, broad-spectrum antimicrobials - the Bisphosphocin class - to treat infectious diseases and reduce the threat posed by antibiotic-resistant bacterial strains, including MRSA, VRE, and others. The company's main product is Nu-3, a topically delivered antimicrobial gel in Phase 2 clinical trials for the treatment of mildly infected diabetic foot ulcers (iDFU). It is also advancing a portfolio of early-stage pipeline compounds developed from its Bisphosphocin platform targeting potential disease indications, including complicated urinary tract infection (cUTI) and pulmonary infections.

Share on Social Networks: